Open account
Sign up/Log in
MARKET
AMGN
AMGN
Amgen Inc
NASDAQ
269.38
-3.63
-1.33%
After Hours: 267.60 -1.78 -0.66% 19:36 04/25 EDT
OPEN
273.45
PREV CLOSE
273.01
HIGH
274.35
LOW
267.24
VOLUME
1.79M
TURNOVER
0
52 WEEK HIGH
329.72
52 WEEK LOW
206.75
MARKET CAP
144.49B
P/E (TTM)
21.58
1D
5D
1M
3M
1Y
5Y
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. The company's main pipeline candidate, CX-904, is being assessed in a phase 1 trial. CTMX has 1.5 years of cash runway to fund operations. Right now, there is a surge of interest in masked immunotherapies.
Seeking Alpha · 13h ago
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
NASDAQ · 18h ago
AstraZeneca rises as oncology business drives Q1 beat
British drugmaker AstraZeneca topped Street forecasts with its Q1 2024 results. Firm's oncology business drives strong sales growth. Astra's London-listed shares rose 5.1% in afternoon trading to highest level since May 2023. The company reported $12.7B in revenue for the quarter.
Seeking Alpha · 23h ago
UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth
AstraZeneca's first-quarter revenue up 19% to $12.68 bln. Oncology revenue up 26% in qtr to $5.12 bn. Anglo-Swedish drugmaker's top business, oncology, clocked a 26% jump in first quarter sales.
Reuters · 1d ago
UPDATE 3-AstraZeneca leaps after smashing first quarter forecasts
AstraZeneca revenue up 19% to $12.68 bln in first quarter. Oncology revenue up 26% in qtr Shares up over 5% in early trading. Shares in the FTSE 100 firm climb to highest since May last year. Company boosted by demand for blockbuster drugs and steady sales from partnered medicines.
Reuters · 1d ago
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Cullinan Therapeutics Inc. Announced its plans to expand into autoimmune diseases. The company's CLN-978 is a similar CD19xCD3 bispecific T-cell engager to Amgen's Blincyto. A recent case study suggests the potential for using B-cell-depleting therapy in autoimmune diseases like systemic lupus erythematosus.
Benzinga · 1d ago
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO)
TipRanks · 2d ago
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.